Provectus reports Phase Ib data for PV-10 in melanoma

In October, Provectus Biopharmaceuticals Inc. (OTCQB:PVCT) reported preliminary data from 10 evaluable patients with stage IV metastatic melanoma in the Phase Ib portion of a Phase Ib/II trial showing that PV-10 (Provecta) plus Keytruda pembrolizumab led to an overall complete response in 10% of patients, overall objective response in 50% of patients and overall clinical benefit in 60% of patients. The product, a sterile injection containing 10% rose bengal disodium, led to a target lesion complete response in 50% of patients and a target lesion objective response in 80% of patients.

No unexpected toxicities or evidence of compounded toxicity were observed. Patients received the combination every three weeks for five cycles, followed by Keytruda alone every three weeks for up to 24 months. Data were presented at the Society for Melanoma Research Congress in Brisbane...